Table of Contents Author Guidelines Submit a Manuscript
Journal of Pharmaceutics
Volume 2016 (2016), Article ID 8961621, 11 pages
http://dx.doi.org/10.1155/2016/8961621
Review Article

Formulations of Amlodipine: A Review

Baqai Institute of Pharmaceutical Sciences, Baqai Medical University, 51 Deh Tor, Toll Plaza, Super Highway, Gadap Road, Karachi 74600, Pakistan

Received 8 July 2016; Accepted 20 September 2016

Academic Editor: Francisco Javier Flores-Murrieta

Copyright © 2016 Muhammad Ali Sheraz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. L. Palma-Gámiz, “High blood pressure and calcium antagonism,” Cardiology, vol. 88, no. 1, pp. 39–46, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. British National Formulary 61, BMJ Group and RPS Publishing, London, UK, 2011.
  3. H.-Y. Lee, H.-J. Kang, B.-K. Koo et al., “Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison,” Clinical Therapeutics, vol. 27, no. 6, pp. 728–739, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. J.-Y. Park, K.-A. Kim, G.-S. Lee et al., “Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects,” Clinical Therapeutics, vol. 26, no. 5, pp. 715–723, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J.-Y. Park, K.-A. Kim, P.-W. Park et al., “Comperative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects,” International Journal of Clinical Pharmacology and Therapeutics, vol. 44, no. 12, pp. 641–647, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. J. Lee, H.-H. Park, S.-H. Koh, N.-Y. Choi, and K.-Y. Lee, “Amlodipine besylate and amlodipine camsylate prevent cortical neuronal cell death induced by oxidative stress,” Journal of Neurochemistry, vol. 119, no. 6, pp. 1262–1270, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. S. C. Sweetman, Martindale: The Complete Drug Reference, Royal Pharmaceutical Society, London, UK, 36th edition, 2009.
  8. Š. Hadžidedić, A. Uzunović, S. Šehić Jazić, and S. Kocova El-Arini, “The impact of chirality on the development of robust and stable tablet formulation of (S-) amlodipine besylate,” Pharmaceutical Development and Technology, vol. 19, no. 8, pp. 930–941, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Goldmann, J. Stoltefuss, and L. Born, “Determination of the absolute configuration of the active amlodipine enantiomer as (-)-S: a correction,” Journal of Medicinal Chemistry, vol. 35, no. 18, pp. 3341–3344, 1992. View at Publisher · View at Google Scholar · View at Scopus
  10. J.-Y. Park, K.-A. Kim, P.-W. Park et al., “Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study,” Clinical Therapeutics, vol. 28, no. 11, pp. 1837–1847, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. X.-P. Zhang, E. L. Kit, S. Mital, S. Chahwala, and T. H. Hintze, “Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine,” Journal of Cardiovascular Pharmacology, vol. 39, no. 2, pp. 208–214, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Khames, “Liquisolid technique: a promising alternative to conventional coating for improvement of drug photostability in solid dosage forms,” Expert Opinion on Drug Delivery, vol. 10, no. 10, pp. 1335–1343, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Fu, S. Yang, S. H. Jeong, S. Kimura, and K. Park, “Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 21, no. 6, pp. 433–475, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Parkash, S. Maan, Deepika, S. Yadav, H. Hemlata, and V. Jogpal, “Fast disintegrating tablets: opportunity in drug delivery system,” Journal of Advanced Pharmaceutical Technology and Research, vol. 2, no. 4, pp. 223–235, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Fukui-Soubou, H. Terashima, K. Kawashima, O. Utsunomiya, and T. Terada, “Efficacy, safety, and palatability of RACTAB® formulation amlodipine orally disintegrating tablets,” Drugs in R & D, vol. 11, no. 4, pp. 327–336, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Uchida, M. Yoshida, M. Hazekawa et al., “Evaluation of palatability of 10 commercial amlodipine orally disintegrating tablets by gustatory sensation testing, OD-mate as a new disintegration apparatus and the artificial taste sensor,” Journal of Pharmacy and Pharmacology, vol. 65, no. 9, pp. 1312–1320, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Liu, J. Jia, G. Liu et al., “Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy chinese male volunteers,” Clinical Therapeutics, vol. 31, no. 4, pp. 777–783, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Ferrarini, A. A. Bianchetti, E. F. Fossali et al., “What can we do to make antihypertensive medications taste better for children?” International Journal of Pharmaceutics, vol. 457, no. 1, pp. 333–336, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Milani, M. Ragazzi, G. D. Simonetti et al., “Superior palatability of crushed lercanidipine compared with amlodipine among children,” British Journal of Clinical Pharmacology, vol. 69, no. 2, pp. 204–206, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Bhardwaj, M. Bansal, and P. K. Sharma, “Formulation and evaluation of fast dissolving tablets of amlodipine besylate using different super disintegrants and camphor as sublimating agent,” American-Eurasian Journal of Scientific Research, vol. 5, pp. 264–269, 2010. View at Google Scholar
  21. G. S. Krushnan, R. M. Britto, J. Perianayagam et al., “Formulation and evaluation of oro dispersible tablets of amlodipine besylate,” Indian Journal of Research in Pharmacy and Biotechnology, vol. 1, pp. 472–477, 2013. View at Google Scholar
  22. B. S. Raj, I. S. R. Punitha, and S. Dube, “Formulation and characterization of fast disintegrating tablets of amlodipine using superdisintegrants,” Journal of Applied Pharmaceutical Science, vol. 2, no. 8, pp. 118–123, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. P. S. Mohanachandran, P. R. Krishna Mohan, S. Fels, K. B. Bini, B. Beenu, and K. K. Shalina, “Formulation and evaluation of mouth dispersible tablets of amlodipine besylate,” International Journal of Applied Pharmaceutics, vol. 2, no. 3, pp. 1–6, 2010. View at Google Scholar
  24. R. Dahima, A. Pachori, and S. Netam, “Formulation and evaluation of mouth dissolving tablet containing amlodipine besylate solid dispersion,” International Journal of ChemTech Research, vol. 2, no. 1, pp. 706–715, 2010. View at Google Scholar · View at Scopus
  25. V. Mascoli, U. Kuruganti, A. T. Bapuji, R. Wang, and B. Damle, “Pharmacokinetics of a novel orodispersible tablet of amlodipine in healthy subjects,” Journal of Bioequivalence and Bioavailability, vol. 5, no. 2, pp. 76–79, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Gokul Ghenge, S. D. Pande, A. Ahmad, L. Jejurkar, and T. Birari, “Development and characterisation of fast disintegrating tablet of amlodipine besylate using mucilage of plantago ovata as a natural superdisintegrant,” International Journal of PharmTech Research, vol. 3, no. 2, pp. 938–945, 2011. View at Google Scholar · View at Scopus
  27. S. Sukhavasi and V. S. Kishore, “Formulation and evaluation of fast dissolving tablets of amlodipine besylate by using Fenugreek seed mucilage and Ocimum basilicum gum,” International Current Pharmaceutical Journal, vol. 1, no. 9, pp. 243–249, 2012. View at Publisher · View at Google Scholar
  28. B. N. Singh and K. H. Kim, “Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention,” Journal of Controlled Release, vol. 63, no. 3, pp. 235–259, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Pare, S. K. Yadav, and U. K. Patil, “Formulation and evaluation of effervescent floating tablet of amlodipine besylate,” Research Journal of Pharmacy and Technology, vol. 1, pp. 526–530, 2008. View at Google Scholar
  30. A. Abebe, I. Akseli, O. Sprockel, N. Kottala, and A. M. Cuitiño, “Review of bilayer tablet technology,” International Journal of Pharmaceutics, vol. 461, no. 1-2, pp. 549–558, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Akseli, A. Abebe, O. Sprockel, and A. M. Cuitiño, “Mechanistic characterization of bilayer tablet formulations,” Powder Technology, vol. 236, pp. 30–36, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Aryal and N. Škalko-Basnet, “Stability of amlodipine besylate and atenolol in multi-component tablets of mono-layer and bi-layer types,” Acta Pharmaceutica, vol. 58, no. 3, pp. 299–308, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Hariharan, M. Sudhakar, and R. Vinay, “Development and optimization of bilayer hydrodyanamically balanced system of Amlodipine Besylate immediate release and Hydrochlorothiazide controlled release,” Asian Journal of Pharmaceutical and Clinical Research, vol. 6, no. 3, pp. 243–246, 2013. View at Google Scholar · View at Scopus
  34. S. Jayaprakash, S. M. Halith, K. Pillai, P. Balasubramaniyam, U. M. Firthouse, and M. Boopathi, “Formulation and evaluation of bilayer tablets of amlodipine besilate and metprolol succinate,” Der Pharmacia Lettre, vol. 3, no. 4, pp. 143–154, 2011. View at Google Scholar · View at Scopus
  35. A. N. Zaid, S. Natur, A. Qaddomi et al., “Formulation and bioequivalence of two valsartan/amlodipine immediate release tablets after a single oral administration,” Pakistan Journal of Pharmaceutical Sciences, vol. 27, no. 4, pp. 755–762, 2014. View at Google Scholar · View at Scopus
  36. K.-L. Chien, C.-L. Chao, and T.-C. Su, “Bioavailability study of fixed-dose tablet versus capsule formulation of amlodipine plus benazepril: a randomized, single-dose, two-sequence, two-period, open-label, crossover study in healthy volunteers,” Current Therapeutic Research—Clinical and Experimental, vol. 66, no. 2, pp. 69–79, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Farrell, V. French Merkley, and N. Ingar, “Reducing pill burden and helping with medication awareness to improve adherence,” Canadian Pharmacists Journal, vol. 146, no. 5, pp. 262–269, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Hagendorff, S. Freytag, A. Müller, and S. Klebs, “Pill burden in hypertensive patients treated with single-pill combination therapy—an observational study,” Advances in Therapy, vol. 30, no. 4, pp. 406–419, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Axthelm, C. Sieder, F. Meister, and E. Kaiser, “Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg,” Current Medical Research and Opinion, vol. 28, no. 1, pp. 69–78, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Glorioso, M. Thomas, C. Troffa et al., “Antihypertensive efficacy and tolerability of aliskiren/amlodipine single- Pill combinations in patients with an inadequate response to aliskiren monotherapy,” Current Vascular Pharmacology, vol. 10, no. 6, pp. 748–755, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Pfeiffer, N. Rennie, C. C. Papst, and J. Zhang, “Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy,” Current Vascular Pharmacology, vol. 10, no. 6, pp. 773–780, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Azushima, K. Uneda, K. Tamura et al., “Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-visit blood pressure variability and parameters of renal and vascular function in hypertensive patients with chronic kidney disease,” BioMed Research International, vol. 2014, Article ID 437087, 7 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Bashir, M. U. Sherwani, I. Shabbir, and A. Batool, “Efficacy of fix dose combination (atorvastatin and amlodipine) in treatment of uncontrolled hypertension and dyslipidemia,” Journal of Ayub Medical College Abbottabad, vol. 23, no. 3, pp. 97–100, 2011. View at Google Scholar · View at Scopus
  44. A. Delgado-Montero and J. L. Zamorano, “Atorvastatin calcium plus amlodipine for the treatment of hypertension,” Expert Opinion on Pharmacotherapy, vol. 13, no. 18, pp. 2673–2685, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Fedacko, D. Pella, P. Jarcuska et al., “Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET (the STRONG DUET study),” Advances in Therapy, vol. 30, no. 1, pp. 60–70, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. M. A. Hussein, R. H. Chapman, J. S. Benner et al., “Does a single-pill antihypertensivelipid-lowering regimen improve adherence in us managed care enrolees? A non-randomized, observational, retrospective study,” American Journal of Cardiovascular Drugs, vol. 10, no. 3, pp. 193–202, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Hradec, J. Zamorano, and S. Sutradhar, “Post hoc analysis of the cluster randomized usual care versus caduet investigation assessing long-term risk (CRUCIAL) trial,” Current Medical Research and Opinion, vol. 29, no. 6, pp. 589–596, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. J.-H. Kim, J. Zamorano, S. Erdine et al., “Reduction in cardiovascular risk using proactive multifactorial intervention versus usual care in younger (<65 years) and older (≥65 years) patients in the CRUCIAL trial,” Current Medical Research and Opinion, vol. 29, no. 5, pp. 453–463, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. J. M. Neutel, W. H. Bestermann, E. M. Dyess et al., “The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study,” Journal of Clinical Hypertension, vol. 11, no. 1, pp. 22–30, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Park, Y. Lee, S. Ko, and B. Cha, “Cost-effectiveness analysis of low density lipoprotein cholesterol-lowering therapy in hypertensive patients with type 2 diabetes in Korea: single-pill regimen (amlodipine/atorvastatin) versus double-pill regimen (amlodipine+atorvastatin),” Epidemiology and Health, vol. 37, Article ID e2015010, 2015. View at Publisher · View at Google Scholar
  51. L. A. Simons, M. Ortiz, and G. Calcino, “Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006–2010,” Medical Journal of Australia, vol. 195, no. 3, pp. 134–137, 2011. View at Google Scholar · View at Scopus
  52. M. Tanaka, R. Nishimura, T. Nishimura et al., “Effect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure/lipid control, oxidative stress, and medication adherence in type 2 diabetic patients,” Diabetology and Metabolic Syndrome, vol. 6, no. 1, article 56, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Rakugi, E. Nakata, E. Sasaki, and T. Kagawa, “Evaluation of the efficacy and tolerability of fixed-dose combination therapy of azilsartan and amlodipine besylate in Japanese patients with grade I to II essential hypertension,” Clinical Therapeutics, vol. 36, no. 5, pp. 711–721, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. N. Reichek, R. B. Devereux, R. A. Rocha et al., “Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension,” Hypertension, vol. 54, no. 4, pp. 731–737, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. P. H. Skoglund, P. Svensson, J. Asp et al., “Amlodipine + benazepril is superior to hydrochlorothiazide + benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH Trial,” Journal of Clinical Hypertension, vol. 17, no. 2, pp. 141–146, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. H.-Y. Lee, Y.-J. Kim, T. Ahn et al., “A randomized, multicenter, double-blind, placebo-controlled, 3 × 3 factorial design, phase II study to evaluate the efficacy and safety of the combination of fimasartan/amlodipine in patients with essential hypertension,” Clinical Therapeutics, vol. 37, no. 11, pp. 2581–2596, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. U. Jadhav, J. Hiremath, D. J. Namjoshi et al., “Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: the EFFICIENT study,” PLoS ONE, vol. 9, no. 4, Article ID e92955, 2014. View at Publisher · View at Google Scholar
  58. P. Kawalec, P. Holko, E. Stawowczyk, Ł. Borowiec, and K. J. Filipiak, “Economic evaluation of single-pill combination of indapamide and amlodipine in the treatment of arterial hypertension in the Polish setting,” Kardiologia Polska, vol. 73, no. 9, pp. 768–780, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. K. P. Garnock-Jones, “Irbesartan/Amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy,” American Journal of Cardiovascular Drugs, vol. 13, no. 2, pp. 141–150, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. L. D. Esposti, S. Saragoni, S. Buda, and E. D. Esposti, “Drug adherence to olmesartan/amlodipine fixed combination in an Italian clinical practice setting,” ClinicoEconomics and Outcomes Research, vol. 6, no. 1, pp. 209–216, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. G. Derosa, A. F. G. Cicero, A. Carbone et al., “Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies,” Expert Opinion on Drug Safety, vol. 12, no. 5, pp. 621–629, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. G. Derosa, A. F. G. Cicero, A. Carbone et al., “RETRACTED: variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies,” Journal of American Society of Hypertension, vol. 7, no. 1, pp. 32–39, 2013. View at Publisher · View at Google Scholar
  63. G. Derosa, A. F. G. Cicero, A. Carbone et al., “Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies,” Journal of Clinical Pharmacy and Therapeutics, vol. 38, no. 1, pp. 48–55, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. G. Derosa, A. F. G. Cicero, A. Carbone et al., “Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients,” Clinical and Experimental Hypertension, vol. 35, no. 5, pp. 301–307, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. G. Derosa, A. F. G. Cicero, A. Carbone et al., “Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation,” European Journal of Pharmaceutical Sciences, vol. 51, no. 1, pp. 26–33, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Derosa, A. F. G. Cicero, A. Carbone et al., “Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients,” Inflammation, vol. 37, no. 1, pp. 154–162, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. M. R. Weir, W. A. Hsueh, S. D. Nesbitt et al., “A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide,” Journal of Clinical Hypertension, vol. 13, no. 6, pp. 404–412, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. E. Angeloni, A. Vitaterna, P. Lombardo, M. Pirelli, and S. Refice, “Single-pill combination therapy in the initial treatment of marked hypertension: a propensity-matched analysis,” Clinical and Experimental Hypertension, vol. 37, no. 5, pp. 404–410, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. W. J. Elliott, “Rationale for a single-pill combination of perindopril arginine and amlodipine besylate,” Journal of the American Society of Hypertension, vol. 9, no. 4, pp. 257–265, 2015. View at Publisher · View at Google Scholar · View at Scopus
  70. P. Kizilirmak and Z. Ongen, “Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine,” Journal of Hypertension, vol. 33, no. 5, pp. 1114–1116, 2015. View at Publisher · View at Google Scholar · View at Scopus
  71. G. Mancia, R. Asmar, C. Amodeo et al., “Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine,” Journal of Hypertension, vol. 33, no. 2, pp. 401–411, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. A. J. Scheen and J. M. Krzesinski, “Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease,” Revue Médicale de Liège, vol. 64, no. 4, pp. 223–227, 2009. View at Google Scholar · View at Scopus
  73. S. S. Billecke and P. A. Marcovitz, “Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension,” Vascular Health and Risk Management, vol. 9, no. 1, pp. 95–104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. J. M. Neutel, G. Mancia, H. R. Black et al., “Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study,” The Journal of Clinical Hypertension, vol. 14, no. 4, pp. 206–215, 2012. View at Publisher · View at Google Scholar
  75. A. M. Sharma, G. Bakris, J. M. Neutel et al., “Single-pill combination of telmisartan/Amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial,” Clinical Therapeutics, vol. 34, no. 3, pp. 537–551, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. D. Zhu, P. Gao, W. Holtbruegge, and C. Huang, “A randomized, double-blind study to evaluate the efficacy and safety of a single-pill combination of telmisartan 80 mg/amlodipine 5 mg versus amlodipine 5 mg in hypertensive Asian patients,” Journal of International Medical Research, vol. 42, no. 1, pp. 52–66, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. D. Zhu, P. Gao, N. Yagi, and H. Schumacher, “Efficacy and tolerability of telmisartan plus amlodipine in Asian patients not adequately controlled on either monotherapy or on low-dose combination therapy,” International Journal of Hypertension, vol. 2014, Article ID 475480, 11 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. O. Baser, L. M. Andrews, L. Wang, and L. Xie, “Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy,” Journal of Medical Economics, vol. 14, no. 5, pp. 576–583, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. N. Braun, H.-J. Ulmer, A. Ansari, R. Handrock, and S. Klebs, “Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination,” Current Medical Research and Opinion, vol. 25, no. 2, pp. 421–430, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. R. Düsing, “Amlodipine/valsartan single pill combination therapy in Chinese patients not controlled on previous monotherapy,” Journal of Thoracic Disease, vol. 7, no. 4, pp. 562–563, 2015. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Eckert, S. B. Freytag, A. Müller, and S. H. G. Klebs, “Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors,” Blood Pressure, vol. 22, no. 1, pp. 11–21, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. B. Ge, W. Peng, Y. Zhang, Y. Wen, C. Liu, and X. Guo, “Effectiveness of valsartan/amlodipine single-pill combination in hypertensive patients with excess body weight: subanalysis of China status II,” Journal of Cardiovascular Pharmacology, vol. 66, no. 5, pp. 497–503, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. J. Huang, N.-L. Sun, Y.-M. Hao et al., “Efficacy and tolerability of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients not adequately controlled with valsartan monotherapy,” Clinical and Experimental Hypertension, vol. 33, no. 3, pp. 179–186, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. D. Hu, L. Liu, and W. Li, “Efficacy and safety of valsartan/amlodipine single-pill combination in 11,422 Chinese patients with hypertension: an observational study,” Advances in Therapy, vol. 31, no. 7, pp. 762–775, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. Y. Karpov, N. Dongre, A. Vigdorchik, and K. Sastravaha, “Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the real-life safety and effectiveness in the routine treatment of hypertension,” Advances in Therapy, vol. 29, no. 2, pp. 134–147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. Y.-N. Ke, J. Huang, and J.-R. Zhu, “Efficacy and safety of the single pill combination of valsartan 80 mg plus amlodipine 5 mg in mild to moderate essential hypertensive patients without adequate blood pressure control by monotherapy,” Zhonghua Xin Xue Guan Bing Za Zhi, vol. 37, no. 9, pp. 794–799, 2009. View at Google Scholar · View at Scopus
  87. Y. Ke, D. Zhu, H. Hong et al., “Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy,” Current Medical Research and Opinion, vol. 26, no. 7, pp. 1705–1713, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. W. Khan, N. Moin, S. Iktidar et al., “Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan,” Therapeutic Advances in Cardiovascular Disease, vol. 8, no. 2, pp. 45–55, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. P. Kizilirmak, M. Berktas, M. R. Yalcin et al., “Efficacy and safety of valsartan and amlodipine single-pill combination in hypertensive patients (PEAK study),” Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır, vol. 41, pp. 406–417, 2013. View at Google Scholar
  90. P. Kızılırmak, I. Ar, and B. Ilerigelen, “Efficacy and safety of valsartan/amlodipine single-pill combination in patients with essential hypertension (PEAK LOW),” Türk Kardiyoloji Derneği arşivi: Türk Kardiyoloji Derneğinin yayın organıdır, vol. 42, no. 4, pp. 339–348, 2014. View at Publisher · View at Google Scholar
  91. R. Lins, A. Aerts, N. Coen et al., “Effectiveness of amlodipine-valsartan single-pill combinations: hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (The Excellent Study),” Annals of Pharmacotherapy, vol. 45, no. 6, pp. 727–739, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. M. A. Malesker and D. E. Hilleman, “Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy,” Managed Care, vol. 19, pp. 36–42, 2010. View at Google Scholar
  93. K. Motozato, S.-I. Miura, Y. Shiga et al., “Efficacy and safety of two single-pill fixed-dose combinations of angiotensin II receptor blockers/calcium channel blockers in hypertensive patients (EXAMINER study),” Clinical and Experimental Hypertension, vol. 38, no. 1, pp. 45–50, 2016. View at Publisher · View at Google Scholar · View at Scopus
  94. A. N. Odili, B. Ezeala-Adikaibe, M. B. Ndiaye et al., “Progress report on the first sub-Saharan Africa trial of newer versus older antihypertensive drugs in native black patients,” Trials, 2012, article 59. View at Publisher · View at Google Scholar · View at Scopus
  95. J. Sison, S. H. Assaad-Khalil, R. Najem et al., “Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study,” Current Medical Research and Opinion, vol. 30, no. 10, pp. 1937–1945, 2014. View at Publisher · View at Google Scholar · View at Scopus
  96. J.-G. Wang, W.-F. Zeng, Y.-S. He et al., “Valsartan/amlodipine compared to nifedipine GITS in patients with hypertension inadequately controlled by monotherapy,” Advances in Therapy, vol. 30, no. 8, pp. 771–783, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Zhu, K. Yang, N. Sun et al., “Amlodipine/valsartan 5/160 mg versus valsartan 160 mg in Chinese hypertensives,” International Journal of Cardiology, vol. 167, no. 5, pp. 2024–2030, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. Y. Huan and R. Townsend, “The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension,” Expert Opinion on Pharmacotherapy, vol. 13, no. 16, pp. 2409–2415, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. M. B. Hovater and E. A. Jaimes, “Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination,” Integrated Blood Pressure Control, vol. 6, pp. 59–67, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. P. A. Sarafidis, “Patient Cases: 1. A patient with apparent compliance,” High Blood Pressure and Cardiovascular Prevention, vol. 22, pp. 15–18, 2015. View at Publisher · View at Google Scholar · View at Scopus
  101. P. Stafylas, A. Mavrodi, G. Kourlaba, and N. Maniadakis, “8C.06: cost-effectiveness of two single-pill triple antihypertensive therapies based on the ambulatory blood pressure measurements,” Journal of Hypertension, vol. 33, article e111, 2015. View at Publisher · View at Google Scholar
  102. L. Xie, F. Frech-Tamas, E. Marrett, and O. Baser, “A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy,” Current Medical Research and Opinion, vol. 30, no. 12, pp. 2415–2422, 2014. View at Publisher · View at Google Scholar · View at Scopus
  103. P. Stafylas, G. Kourlaba, M. Hatzikou, D. Georgiopoulos, P. Sarafidis, and N. Maniadakis, “Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components,” Cost Effectiveness and Resource Allocation, vol. 13, no. 1, article 10, 2015. View at Publisher · View at Google Scholar · View at Scopus
  104. V. K. Tyagi, D. Singh, and K. Pathak, “Semisolid matrix-filled hard gelatin capsules for rapid dissolution of amlodipine besilate: development and assessment,” Journal of Advanced Pharmaceutical Technology and Research, vol. 4, no. 1, pp. 42–49, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. S. Garg, K. Pathak, A. Philip, and D. Puri, “Osmotically regulated two-compartment asymmetric membrane capsules for simultaneous controlled release of anti-hypertensive drugs,” Scientia Pharmaceutica, vol. 80, no. 1, pp. 229–250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. P. V. Shelke, A. S. Dumbare, M. V. Gadhave et al., “Formulation and evaluation of rapidly disintegrating film of amlodipine besylate,” Journal of Drug Delivery and Therapeutics, vol. 2, pp. 72–75, 2012. View at Google Scholar
  107. M. C. Nahata, R. S. Morosco, and T. F. Hipple, “Stability of amlodipine besylate in two liquid dosage forms,” Journal of the American Pharmaceutical Association, vol. 39, no. 3, pp. 375–377, 1999. View at Publisher · View at Google Scholar · View at Scopus
  108. D. A. Lyszkiewicz, Z. Levichek, E. Kozer et al., “Bioavailability of a pediatric amlodipine suspension,” Pediatric Nephrology, vol. 18, no. 7, pp. 675–678, 2003. View at Google Scholar · View at Scopus
  109. N. L. Rivero, I. A. Santos, and A. P. Carreiro, “Amlodipine in pediatric patient with uncontrolled multifactorial hypertension. Formulation of amlodipine oral suspension,” European Review for Medical and Pharmacological Sciences, vol. 16, no. 8, pp. 1117–1119, 2012. View at Google Scholar · View at Scopus
  110. D. Kumar, M. Aqil, M. Rizwan, Y. Sultana, and M. Ali, “Investigation of a nanoemulsion as vehicle for transdermal delivery of amlodipine,” Pharmazie, vol. 64, no. 2, pp. 80–85, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. G. Chhabra, K. Chuttani, A. K. Mishra, and K. Pathak, “Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability,” Drug Development and Industrial Pharmacy, vol. 37, no. 8, pp. 907–916, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. D.-J. Jang, E. J. Jeong, H.-M. Lee, B.-C. Kim, S.-J. Lim, and C.-K. Kim, “Improvement of bioavailability and photostability of amlodipine using redispersible dry emulsion,” European Journal of Pharmaceutical Sciences, vol. 28, no. 5, pp. 405–411, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. R. M. Mainardes, M. C. Urban, P. O. Cinto, M. V. Chaud, R. C. Evangelista, and M. P. D. Gremião, “Liposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery,” Current Drug Delivery, vol. 3, no. 3, pp. 275–285, 2006. View at Publisher · View at Google Scholar · View at Scopus
  114. K. R. Jadhav, M. N. Gambhire, I. M. Shaikh, V. J. Kadam, and S. S. Pisal, “Nasal drug delivery system-factors affecting and applications,” Current Drug Therapy, vol. 2, no. 1, pp. 27–38, 2007. View at Publisher · View at Google Scholar · View at Scopus
  115. G. Ragno, E. Cione, A. Garofalo et al., “Design and monitoring of photostability systems for amlodipine dosage forms,” International Journal of Pharmaceutics, vol. 265, no. 1-2, pp. 125–132, 2003. View at Publisher · View at Google Scholar · View at Scopus
  116. S. Patil and R. Murthy, “Preparation and in vitro evaluation of mucoadhesive chitosan microspheres of amlodipine besylate for nasal administration,” Indian Journal of Pharmaceutical Sciences, vol. 68, no. 1, pp. 64–67, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. N. G. N. Swamy and Z. Abbas, “Preparation and in vitro characterization of mucoadhesive hydroxypropyl guar microspheres containing amlodipine besylate for nasal administration,” Indian Journal of Pharmaceutical Sciences, vol. 73, no. 6, pp. 608–614, 2011. View at Publisher · View at Google Scholar · View at Scopus
  118. X. Wang, X. Zhang, Y. Qin, L. Zhong, K. Liu, and J. Zhang, “Percutaneous penetration ability of dexamethasone-amlodipine besylate compound gel and its effect on survival of ischemic random skin flap,” Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, vol. 24, no. 5, pp. 566–570, 2010. View at Google Scholar · View at Scopus
  119. W. Mixon and S. R. Helms, “Transdermal amlodipine besylate in Lipoderm for the treatment of feline hypertension: a report of two cases,” International Journal of Pharmaceutical Compounding, vol. 12, no. 5, pp. 392–397, 2008. View at Google Scholar · View at Scopus
  120. M. S. Kamble, S. M. Dange, K. K. Bhalerao et al., “Development and evaluation of amlodipine besylate nanogel,” Journal of Bionanoscience, vol. 9, no. 1, pp. 22–27, 2015. View at Publisher · View at Google Scholar · View at Scopus
  121. Y. Sun, L. Fang, M. Zhu et al., “A drug-in-adhesive transdermal patch for S-amlodipine free base: in vitro and in vivo characterization,” International Journal of Pharmaceutics, vol. 382, no. 1-2, pp. 165–171, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. H. V. Patel, S. S. Patel, M. M. Raj et al., “Development and characterization of matrix-membrane controlled transdermal drug delivery system of amlodipine besylate,” Indo American Journal of Pharmaceutical Research, vol. 4, pp. 5306–5314, 2014. View at Google Scholar
  123. M. G. Quaglia, F. Barbato, S. Fanali et al., “Direct determination by capillary electrophoresis of cardiovascular drugs, previously included in liposomes,” Journal of Pharmaceutical and Biomedical Analysis, vol. 37, no. 1, pp. 73–79, 2005. View at Publisher · View at Google Scholar · View at Scopus
  124. X. Li, G.-R. Ruan, W.-L. Lu et al., “A novel stealth liposomal topotecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia,” Journal of Controlled Release, vol. 112, no. 2, pp. 186–198, 2006. View at Publisher · View at Google Scholar · View at Scopus
  125. X. Li, W. L. Lu, G. W. Liang et al., “Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice,” European Journal of Clinical Investigation, vol. 36, no. 6, pp. 409–418, 2006. View at Publisher · View at Google Scholar · View at Scopus
  126. R. P. Mason, I. T. Mak, M. W. Trumbore, and P. E. Mason, “Antioxidant properties of calcium antagonists related to membrane biophysical interactions,” American Journal of Cardiology, vol. 84, no. 4, pp. 16–22, 1999. View at Publisher · View at Google Scholar · View at Scopus
  127. R. P. Mason, P. R. Leeds, R. F. Jacob et al., “Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells,” Journal of Neurochemistry, vol. 72, no. 4, pp. 1448–1456, 1999. View at Publisher · View at Google Scholar · View at Scopus
  128. R. P. Mason, M. W. Trumbore, and P. E. Mason, “Membrane biopphysical interactions of amlodipine result in antioxidant properties,” Drugs, vol. 59, no. 2, pp. 9–16, 2000. View at Google Scholar · View at Scopus
  129. Y. Zhang, R.-J. Li, X. Ying et al., “Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer,” Molecular Pharmaceutics, vol. 8, no. 1, pp. 162–175, 2011. View at Publisher · View at Google Scholar · View at Scopus